Vax2Muc researchers map out future collaboration

Eight months into the project, a group of Vax2Muc researchers from Helmholtz Centre for Infection Research (HZI), Statens Serum Institut (SSI), Technical University of Munich (TUM), and Trinity College Dublin (TCD) met in Munich to jointly explore technics and protocols for their future collaboration.

To safeguard the highest research standards and obtain insights that allow for replication and validation afterwards, the team agreed on the Standard Operating Procedures necessary to perform specific tasks or experiments consistently and safely across all sites. More concretely, the aim was to ensure that all partners involved in the upcoming in vivo studies are as equipped as possible.

In the coming months, the plan is to begin the murine vaccination studies at the partner sites HZI, SSI, TCD, and TUM to evaluate our vaccine candidate against Helicobacter pylori in various settings.

The lab exchange showcases Vax2Muc’s commitment to collaboration and ensuring that best practices are shared and implemented across the team. Step by step, the project is paving the way for its ambitious goal: developing a vaccine that is effective against diseases caused by antimicrobial-resistant (AMR) bacterial pathogens that colonise the gastrointestinal tract.

Elena Reinhard (HZI), Jeanne Toft Jakobsen (SSI), Ruolan Gong (TUM), Thomas Ebensen (HZI), Nicole O'Sullivan (TCD), Cora Mibus (TUM) (from left to right)

Vax2Muc is funded by the Horizon Europe research and innovation programme and runs for five years until June 2028.